End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.11 CNY | -0.43% |
|
-3.51% | +10.68% |
26/04 | Jiang Zhong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
25/03 | Jiang Zhong Pharmaceutical Co.,Ltd Proposes Cash Dividend | CI |
Strengths
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.68% | 198.07Cr | - | ||
+55.32% | 82TCr | C+ | ||
+44.05% | 64TCr | B | ||
-6.75% | 35TCr | C+ | ||
+13.56% | 31TCr | B- | ||
+10.68% | 30TCr | C+ | ||
+16.57% | 24TCr | B+ | ||
+13.31% | 22TCr | B- | ||
+8.48% | 17TCr | C+ | ||
-2.81% | 16TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 600750 Stock
- Ratings Jiang Zhong Pharmaceutical Co.,Ltd